TenatoprazoleCAS# 113712-98-4 |
- AZD8055
Catalog No.:BCC3629
CAS No.:1009298-09-2
- WYE-354
Catalog No.:BCC1059
CAS No.:1062169-56-5
- GDC-0349
Catalog No.:BCC1094
CAS No.:1207360-89-1
- Everolimus (RAD001)
Catalog No.:BCC3594
CAS No.:159351-69-6
- Rapamycin (Sirolimus)
Catalog No.:BCC3592
CAS No.:53123-88-9
- KU-0063794
Catalog No.:BCC2484
CAS No.:938440-64-3
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 113712-98-4 | SDF | Download SDF |
| PubChem ID | 636411 | Appearance | Powder |
| Formula | C16H18N4O3S | M.Wt | 346.4 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO | ||
| Chemical Name | 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine | ||
| SMILES | CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=CC(=N3)OC | ||
| Standard InChIKey | ZBFDAUIVDSSISP-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C16H18N4O3S/c1-9-7-17-12(10(2)14(9)23-4)8-24(21)16-18-11-5-6-13(22-3)19-15(11)20-16/h5-7H,8H2,1-4H3,(H,18,19,20) | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Tenatoprazole Dilution Calculator
Tenatoprazole Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.8868 mL | 14.4342 mL | 28.8684 mL | 57.7367 mL | 72.1709 mL |
| 5 mM | 0.5774 mL | 2.8868 mL | 5.7737 mL | 11.5473 mL | 14.4342 mL |
| 10 mM | 0.2887 mL | 1.4434 mL | 2.8868 mL | 5.7737 mL | 7.2171 mL |
| 50 mM | 0.0577 mL | 0.2887 mL | 0.5774 mL | 1.1547 mL | 1.4434 mL |
| 100 mM | 0.0289 mL | 0.1443 mL | 0.2887 mL | 0.5774 mL | 0.7217 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Tenatoprazole is a prodrug of the proton pump inhibitor (PPI) class, which inhibits proton transport with IC50 of 3.2 μM.
- BOC-D-ARG-OH.HCL.H2O
Catalog No.:BCC3069
CAS No.:113712-06-4
- 4-Aminobenzophenone
Catalog No.:BCC8684
CAS No.:1137-41-3
- Shizukanolide H
Catalog No.:BCN6016
CAS No.:1136932-34-7
- 3-(hydroxymethyl)cyclopentanone
Catalog No.:BCN6015
CAS No.:113681-11-1
- Neuropeptide Y 13-36 (porcine)
Catalog No.:BCC6959
CAS No.:113662-54-7
- Ustusolate A
Catalog No.:BCN6756
CAS No.:1136611-58-9
- IDE 2
Catalog No.:BCC6099
CAS No.:1136466-93-7
- Stigmast-4-ene-3,6-diol
Catalog No.:BCN6014
CAS No.:113626-76-9
- Metasequoic acid A
Catalog No.:BCN6652
CAS No.:113626-22-5
- 6beta-(Hexa-2,4-dienoyloxy)-9alpha,12-dihydroxydrimenol
Catalog No.:BCN7277
CAS No.:1136245-81-2
- Orbifloxacin
Catalog No.:BCC4689
CAS No.:113617-63-3
- Tigecycline mesylate
Catalog No.:BCC4229
CAS No.:1135871-27-0
- cis-Ned 19
Catalog No.:BCC6089
CAS No.:1137264-00-6
- BRD 7552
Catalog No.:BCC8035
CAS No.:1137359-47-7
- LX1606
Catalog No.:BCC1713
CAS No.:1137608-69-5
- Ilexhainanoside D
Catalog No.:BCN7863
CAS No.:1137648-52-2
- Eudesm-4(15)-ene-3alpha,11-diol
Catalog No.:BCN4060
CAS No.:113773-90-3
- Dexmedetomidine
Catalog No.:BCC4326
CAS No.:113775-47-6
- MDL 72832 hydrochloride
Catalog No.:BCC6637
CAS No.:113777-40-5
- TAK960
Catalog No.:BCC6411
CAS No.:1137868-52-0
- (Z)-FeCP-oxindole
Catalog No.:BCC6079
CAS No.:1137967-28-2
- Z-Gly-OH
Catalog No.:BCC2770
CAS No.:1138-80-3
- Picrasidine T
Catalog No.:BCN6017
CAS No.:113808-03-0
- N1,N12-Diethylspermine tetrahydrochloride
Catalog No.:BCC6669
CAS No.:113812-15-0
Determination of tenatoprazole enantiomers and their enantioselective pharmacokinetics in rats.[Pubmed:18752288]
Chirality. 2009 Jun;21(6):613-8.
The enantioselective pharmacokinetics of Tenatoprazole were studied in Wistar rats after the administration of a single oral dose of rac-Tenatoprazole. Serial plasma samples were collected; and the pharmacokinetic behavior of each enantiomer was characterized using a sequential achiral and chiral liquid chromatographic method. Tenatoprazole was extracted from a small aliquot of plasma (100 microl) by one-step extraction using hexane-dichloromethane-isopropanol (20:10:1, v/v/v) as extract solvent. Plasma drug concentration-time data were analyzed for each enantiomer by using a noncompartmental method. The AUC(0-infinity) and C(max) values of (+)-Tenatoprazole were significantly greater than those of (-)-Tenatoprazole (P < 0.001). The mean AUC(0-infinity) value of (+)-Tenatoprazole was 7.5 times greater than that of (-)-Tenatoprazole after oral administration of rac-Tenatoprazole to rats at a dose of 5 mg/kg. There are also significant differences in t(1/2) and CL/F (P < 0.01 and P < 0.001, respectively) values between enantiomers. This study suggests that the pharmacokinetics of Tenatoprazole are enantioselective in rats.
The pharmacodynamics and pharmacokinetics of S-tenatoprazole-Na 30 mg, 60 mg and 90 mg vs. esomeprazole 40 mg in healthy male subjects.[Pubmed:20015104]
Aliment Pharmacol Ther. 2010 Mar;31(6):648-57.
BACKGROUND: Racemic Tenatoprazole 40 mg/day provides more prolonged acid suppression than esomeprazole 40 mg/day. AIM: To compare pharmacodynamic and pharmacokinetic profiles of Tenatoprazole and esomeprazole. METHODS: A single-centre, double-blind, double-dummy, randomized, 4-way, cross-over study was conducted in 32 healthy male subjects. S-Tenatoprazole-Na 30, 60 or 90 mg, or esomeprazole 40 mg was administered once daily for 5 days with 10-day washout intervals. The 24-h intragastric pH was recorded at baseline and on day 5 of each period. RESULTS: On day 5, median pH (5.34 +/- 0.45 and 5.19 +/- 0.52 vs. 4.76 +/- 0.82, respectively, P < 0.002) and percentage time with pH > 4 (80 +/- 11 and 77 +/- 12, vs. 63 +/- 11 respectively, P < 0.0001) for 24-h were higher with S-Tenatoprazole-Na 90 mg and 60 mg than esomeprazole. In nocturnal periods, S-Tenatoprazole-Na 90 mg, 60 mg and 30 mg were superior to esomeprazole with regard to median pH (5.14 +/- 0.64, 4.94 +/- 0.65, 4.65 +/- 0.86 and 3.69 +/- 1.18 respectively, P < 0.0001) and percentage time with pH > 4 (77 +/- 12, 73 +/- 17, 64 +/- 17 and 46 +/- 17 respectively, P < 0.0001). Proportion of subjects with nocturnal acid breakthrough with S-Tenatoprazole-Na 90 mg, 60 mg and 30 mg was significantly less than with esomeprazole (54.8, 43.3, 56.7 and 90.3 respectively, P < 0.04). The proportion of subjects with >16 hrs with pH >4 was significantly higher with S-Tenatoprazole-Na 90 mg and 60 mg than with esomeprazole (87.1%, 83.3% and 41.9% respectively, P < 0.02). CONCLUSIONS: S-Tenatoprazole-Na produced significantly greater and more prolonged dose-dependent 24-h and nocturnal acid suppression than esomeprazole. S-Tenatoprazole-Na may provide greater clinical efficacy compared with current PPIs for patients with ineffective once-daily therapy.
Application of a stability-indicating thin-layer chromatographic method to the determination of tenatoprazole in pharmaceutical dosage forms.[Pubmed:19485196]
J AOAC Int. 2009 Mar-Apr;92(2):387-93.
A sensitive, selective, precise, and stability-indicating thin-layer chromatographic (TLC) method was developed and validated for the determination of Tenatoprazole both as a bulk drug and in formulation. The method uses TLC aluminum plates precoated with Silica Gel 60F-254 as the stationary phase and the solvent system toluene-ethyl acetate-methanol (6 + 4 + 1, v/v/v). This system gave compact spots for Tenatoprazole (Rf value of 0.34 +/- 0.02). Tenatoprazole was subjected to acid and alkali hydrolysis, oxidation, and photodegradation. The peaks of the degradation products were well-resolved from that of the pure drug and had significantly different Rf values. Densitometric analysis of Tenatoprazole was performed in the absorbance mode at 306 nm. The linear regression analysis data for the calibration plots showed a good linear relationship over the concentration range of 100-1500 ng/spot. The mean values of the correlation coefficient, slope, and intercept were 0.9989 +/- 1.42, 10.27 +/- 0.965, and 4894.2 +/- 1.24, respectively. The method was validated for precision, robustness, and recovery. The limit of detection and limit of quantitation were 50 and 100 ng/spot, respectively. Statistical analysis showed that the method is repeatable and selective for estimation of Tenatoprazole. Because the method can separate the drug from its degradation products, it can be used to monitor stability.
LC-UV and LC-MS evaluation of stress degradation behaviour of tenatoprazole.[Pubmed:19615841]
J Pharm Biomed Anal. 2009 Dec 5;50(5):787-93.
In the present study, comprehensive stress testing of Tenatoprazole was carried out according to ICH guideline Q1A (R2). Tenatoprazole was subjected to stress conditions of hydrolysis, oxidation, photolysis and neutral decomposition. Additionally, the solid drug was subjected to 50 degrees C for 60 days in dry-bath, and to the combined effect of temperature and humidity at 40 degrees C/75% RH. Extensive degradation was found to occur in acidic, neutral and oxidative conditions. Mild degradation was observed in basic conditions. The drug is relatively stable in the solid-state. The products formed under different stress conditions were investigated by LC and LC-MS. Successful separation of drug from degradation products formed under stress conditions was achieved on a Chemito ODS-3 column [C18 (5 microm, 250 mm x 4.6 mm, i.d.)] using methanol: 0.01 M acetate buffer pH 4.5 adjusted with glacial acetic acid (55:45) as the mobile phase at flow rate of 1 mL/min and the peak was detected using a UV detector set at 306 nm. The LC-MS m/z values and fragmentation patterns of degradation products formed under different stress conditions were studied and characterized through LC-MS fragmentation. Based on the results, degradation pathway for drug has been proposed.
